Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.

Lee J, Lee C, Kim TH, Chi SC, Moon HR, Oh KT, Lee ES, Lee KC, Youn YS.

Regul Pept. 2012 Aug 20;177(1-3):68-72. doi: 10.1016/j.regpep.2012.04.010. Epub 2012 May 4.

PMID:
22561689
[PubMed - indexed for MEDLINE]
2.

Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.

Lee J, Lee C, Kim I, Moon HR, Kim TH, Oh KT, Lee ES, Lee KC, Youn YS.

Int J Pharm. 2012 Mar 15;424(1-2):50-7. doi: 10.1016/j.ijpharm.2011.12.050. Epub 2011 Dec 31.

PMID:
22226877
[PubMed - indexed for MEDLINE]
3.

Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.

Kim H, Lee J, Kim TH, Lee ES, Oh KT, Lee DH, Park ES, Bae YH, Lee KC, Youn YS.

Pharm Res. 2011 Aug;28(8):2008-19. doi: 10.1007/s11095-011-0427-4. Epub 2011 Apr 7.

PMID:
21472489
[PubMed - indexed for MEDLINE]
4.

Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.

Lee J, Lee C, Kim TH, Lee ES, Shin BS, Chi SC, Park ES, Lee KC, Youn YS.

J Control Release. 2012 Aug 10;161(3):728-34. doi: 10.1016/j.jconrel.2012.05.029. Epub 2012 May 22.

PMID:
22634071
[PubMed - indexed for MEDLINE]
5.

Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.

Lee C, Choi JS, Kim I, Oh KT, Lee ES, Park ES, Lee KC, Youn YS.

Int J Nanomedicine. 2013;8:2975-83. doi: 10.2147/IJN.S48197. Epub 2013 Aug 9.

PMID:
23976850
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.

Kim I, Kim TH, Ma K, Lee ES, Kim D, Oh KT, Lee DH, Lee KC, Youn YS.

Bioconjug Chem. 2010 Aug 18;21(8):1513-9. doi: 10.1021/bc100143c. Erratum in: Bioconjug Chem. 2010 Dec 15;21(12):2361.

PMID:
20715855
[PubMed - indexed for MEDLINE]
7.

Low molecular weight (1‚ÄČkDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.

Kim TH, Park CW, Kim HY, Chi MH, Lee SK, Song YM, Jiang HH, Lim SM, Youn YS, Lee KC.

Biol Pharm Bull. 2012;35(7):1076-83.

PMID:
22791155
[PubMed - indexed for MEDLINE]
Free Article
8.

Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics.

Kim TH, Jiang HH, Lee S, Youn YS, Park CW, Byun Y, Chen X, Lee KC.

Bioconjug Chem. 2011 Apr 20;22(4):625-32. doi: 10.1021/bc100404x. Epub 2011 Mar 14.

PMID:
21401109
[PubMed - indexed for MEDLINE]
9.

A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.

Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC.

J Control Release. 2009 Feb 10;133(3):172-7. doi: 10.1016/j.jconrel.2008.09.091. Epub 2008 Oct 21.

PMID:
18977255
[PubMed - indexed for MEDLINE]
10.

Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.

Kim H, Park H, Lee J, Kim TH, Lee ES, Oh KT, Lee KC, Youn YS.

Biomaterials. 2011 Feb;32(6):1685-93. doi: 10.1016/j.biomaterials.2010.10.045. Epub 2010 Dec 3.

PMID:
21126761
[PubMed - indexed for MEDLINE]
11.

A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action.

Kim I, Kim TH, Ma K, Park ES, Oh KT, Lee ES, Lee KC, Youn YS.

Regul Pept. 2011 Apr 11;167(2-3):239-45. doi: 10.1016/j.regpep.2011.02.008. Epub 2011 Feb 15.

PMID:
21329731
[PubMed - indexed for MEDLINE]
12.

Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats.

Malendowicz LK, Neri G, Nussdorfer GG, Nowak KW, Zyterska A, Ziolkowska A.

Int J Mol Med. 2003 Oct;12(4):593-6.

PMID:
12964040
[PubMed - indexed for MEDLINE]
13.

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.

Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM.

Diabetologia. 1999 Jan;42(1):45-50.

PMID:
10027577
[PubMed - indexed for MEDLINE]
14.

Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.

Kwon KC, Nityanandam R, New JS, Daniell H.

Plant Biotechnol J. 2013 Jan;11(1):77-86. doi: 10.1111/pbi.12008. Epub 2012 Oct 18.

PMID:
23078126
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.

Kim TH, Jiang HH, Lim SM, Youn YS, Choi KY, Lee S, Chen X, Byun Y, Lee KC.

Bioconjug Chem. 2012 Nov 21;23(11):2214-20. doi: 10.1021/bc300265n. Epub 2012 Nov 9.

PMID:
23116483
[PubMed - indexed for MEDLINE]
16.

Down-regulation of zinc transporter 8 in the pancreas of db/db mice is rescued by Exendin-4 administration.

Liu BY, Jiang Y, Lu Z, Li S, Lu D, Chen B.

Mol Med Rep. 2011 Jan-Feb;4(1):47-52. doi: 10.3892/mmr.2010.392. Epub 2010 Nov 1.

PMID:
21461562
[PubMed - indexed for MEDLINE]
17.

Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.

Lee C, Choi JS, Kim I, Byeon HJ, Kim TH, Oh KT, Lee ES, Lee KC, Youn YS.

Acta Biomater. 2014 Feb;10(2):812-20. doi: 10.1016/j.actbio.2013.10.009. Epub 2013 Oct 17.

PMID:
24140611
[PubMed - in process]
18.

Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.

Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA.

Int J Pharm. 2008 May 22;356(1-2):231-8. doi: 10.1016/j.ijpharm.2008.01.015. Epub 2008 Jan 17.

PMID:
18291606
[PubMed - indexed for MEDLINE]
19.

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M.

Diabetes. 1999 May;48(5):1026-34.

PMID:
10331407
[PubMed - indexed for MEDLINE]
Free Article
20.

Biological activity of AC3174, a peptide analog of exendin-4.

Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM.

Regul Pept. 2007 Jun 7;141(1-3):113-9. Epub 2007 Jan 11.

PMID:
17292977
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk